A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

This is an open label extension (OLE) study of an ongoing randomized controlled parent clinical studies 218224 (NCT05878717) and 221672 (NCT06572384) which aim to assess the efficacy and safety of belimumab on reducing the decline in lung function in participants with interstitial lung disease associated with diffuse cutaneous systemic sclerosis (dcSSc-ILD) and interstitial lung disease associated with other connective tissue diseases (CTD-ILD), respectively. The OLE study will describe how well tolerated belimumab will be long term, and whether it might continue to slow progression of lung function decline, slow overall disease progression and improve quality of life.

NCT Number	NCT06716606
Lead Sponsor	GlaxoSmithKline Collaborators: ICON plc
Conditions	Connective Tissue Diseases
Enrollment	514 participants
Start Date	2024-12-12
Primary Completion	2029-12-27 (estimated)
Study Completion	2029-12-27 (estimated)
Updated on ClinicalTrials.gov	2025-12-09